The Oncology Institute, Inc. (TOI)

What is The Oncology Institute?

The Oncology Institute is a physician-owned and affiliated network of outpatient cancer-treatment centers across the United States. Rather than operate as a traditional hospital system or a small independent practice, the company sits between those extremes: it runs multiple locations that deliver chemotherapy, radiation therapy, immunotherapy, and supportive-care services, primarily to patients with solid tumors and blood cancers. Physicians—both oncologists and hematologists—hold equity stakes and participate in governance, which the company argues creates alignment between doctor judgment and business incentives. The business model is straightforward: treat cancer patients, bill insurance and patients directly, and manage the clinic network efficiently enough to turn a margin.

The company’s centers serve a dual function. They are first clinical environments where oncologists diagnose cancer, design treatment regimens, and monitor patients through chemotherapy and related therapies. They are also revenue-generating businesses, in that the company captures payment from insurance companies (private, Medicare, Medicaid) and patients for the infusions, medications, imaging, and associated services rendered. This makes The Oncology Institute partly a healthcare delivery enterprise and partly a medical billing operation—the latter being far more visible in competitive dynamics and margins than many patients realize.

How does The Oncology Institute make money?

Revenue comes from two broad buckets. The first is clinical services revenue, which flows from billing insurance and patients for the actual treatment delivered—chemotherapy infusions, radiation sessions, imaging scans, blood work, and oncology consultations. Insurance typically reimburses based on standardized payment codes and rates; Medicare and Medicaid pay fixed amounts per procedure, while commercial insurance often negotiates discounts below list price. A single chemotherapy infusion might generate anywhere from hundreds to thousands of dollars in billing, depending on the drugs, the combination, the facility, and the payer. Radiation therapy, which is less consumable-intensive than chemotherapy, often carries lower revenue per session. Imaging and lab work add incremental revenue and margin.

The second bucket is ancillary revenue from complementary services: infusion-center operations, survivorship programs, supportive care (nutritional support, counseling), and in some cases home-based infusions or specialty pharmacy services. These can drive margin because they leverage the existing patient relationships and infrastructure.

The business is capital-intensive to start—building and equipping an infusion center requires significant upfront investment—but once operating, the clinics are relatively stable cash generators, provided patient volume holds. The company reinvests some of that cash to expand the network, acquire other oncology practices, and improve operations. Physician partners benefit from a combination of salary or base compensation and a share in the profits of their centers, creating incentives to bring in patients and operate efficiently.

Who are The Oncology Institute’s competitors?

The competitive landscape is fragmented but intensifying. On one end are massive integrated health systems—Mayo, Cleveland Clinic, Johns Hopkins, and numerous regional hospital networks—that have oncology divisions and can leverage scale, name recognition, and the ability to shift patients between services. These systems have deep capital, relationships with primary-care physicians, and the ability to negotiate with insurance companies from a position of strength. On the other end are independent single-practice oncologists and small groups that operate one or two infusion centers and may lack the scale to negotiate attractive rates or manage the administrative burden of modern healthcare billing. In the middle sits a crowded field of regional and national chains: Cancer Treatment Centers of America (formerly a national name, now part of Momentum Health), Compassus, Oncology partners, and others that pursue the same model of multi-location networks under centralized management.

Star Group competes by claiming advantages in three areas. The first is physician alignment: because oncologists own stakes, the company argues that clinical judgment is not subordinated to profits, and that research and innovation receive more attention than in larger systems where oncology is one of many divisions. The second is local decision-making: instead of headquarters mandates, local physician partners have autonomy in hiring, purchasing, and clinical protocols, allowing customization to local patient populations and relationships. The third is agility: without the bureaucratic overhead of hospital systems, the company aims to adopt new therapies and treatment innovations faster than competitors. Whether these advantages are real or marketing claims is difficult to determine without inside knowledge; what matters is whether they translate to better outcomes and market share.

What are the risks and pressures?

The business faces several structural headwinds. The first is pricing pressure. Insurance companies and government payers are constantly scrutinizing oncology spending and pushing back against price increases. As drug costs have exploded and biosimilars have entered the market, the landscape of what insurers will reimburse has become more complex and lower. A reimbursement cut by Medicare or a renegotiation with a large Blue Cross plan can significantly impact revenue without any change to clinical volume.

The second is consolidation. Large hospital systems, private equity firms, and national chains are actively buying independent and small-group oncology practices. This consolidation reduces the number of competitors, but it also concentrates market power in the hands of larger players that can negotiate with suppliers and payers from positions of strength. For The Oncology Institute to remain independent, it must grow through acquisition and network expansion fast enough to remain competitive.

The third is clinical risk. Cancer treatment is complex; outcomes vary, and lawsuits and regulatory actions around the quality of care, patient complications, or inappropriate billing are possible. Any major clinical failure or compliance issue can damage reputation and trigger investigations.

The fourth is payer and regulatory risk. Changes to Medicare or Medicaid reimbursement, or new regulations around oncology care—such as mandates for value-based payment models or site-neutral payment rates that compress the premium oncologists can charge for hospital-based versus clinic-based care—would reshape the business. The rise of insurance-company pressure for step therapy (requiring cheaper treatments first) also constrains the scope of care and physician autonomy.

The fifth is supply-chain volatility. Chemotherapy drugs, especially generic and off-patent drugs, have experienced repeated shortages and price spikes. Dependency on a handful of suppliers for critical drugs creates operational and margin risk.

How should an investor research The Oncology Institute?

Start with the company’s quarterly and annual filings and earnings call transcripts. Pay close attention to patient volume trends (measured in patient visits or treatment sessions) and the average revenue per patient or per session—these are the fundamental drivers of the business. If volume is stable and average revenue is rising, margins likely improve. If volume is falling or average revenue is declining, trouble ahead.

Examine the payer mix. If a large percentage of revenue comes from a single major insurance company or from Medicare, concentration risk is elevated, and a renegotiation or change in policy by that payer could have outsized impact. Watch for quarterly disclosure of any significant contract renegotiations or payer disputes.

Monitor gross margins by service line, if disclosed. Chemotherapy infusions may carry different margins than radiation or imaging; understanding the mix helps forecast profitability. Also track selling, general, and administrative expenses as a percentage of revenue. Efficient operators keep this ratio low; bloated operators have high overhead that eventually constrains returns.

Look at acquisition activity. Is the company actively buying other oncology practices and integrating them successfully, or are acquisitions a drag on margins? Integration risk is real, and overpaying for assets is a classic way to destroy shareholder value.

Finally, stay attuned to regulatory and legislative developments. Changes to Medicare reimbursement, new antitrust scrutiny of health-system consolidation, or shifts in value-based-care policy can reshape the business overnight. The company’s ability to navigate these changes and adapt its model is as important to long-term success as clinical excellence.